Sapere Bio - About the company
Sapere Bio is a seed company based in Raleigh (United States), founded in 2013 by Natalia Mitin and Norman Sharpless. It operates as a Diagnostic company that develops non-invasive biomarker tests to measure cellular aging and predict the risk of age-related diseases. Sapere Bio has raised $500K in funding. The company has 535 active competitors, including 144 funded and 120 that have exited. Its top competitors include companies like Guardant Health, Natera and Myriad Genetics.
Company Details
Sapere Bio is a life sciences company that focuses on developing diagnostic tests to measure biological age, which predicts an individual's risk of chronic diseases. The company's innovative approach involves analyzing a patient's cellular senescence and immune system to identify potential health risks. With a strong team led by Dr. Natalia Mitin, CEO and President, Sapere Bio aims to revolutionize personalized medicine by providing healthcare professionals with actionable insights into a patient's health status.
- Website
- saperebio.com
- Email ID
- *****@saperebio.com
- Phone Number
- +1 **********
Key Metrics
Founded Year
2013
Location
Raleigh, United States
Stage
Seed
Total Funding
$500K in 5 rounds
Latest Funding Round
Investors
Ranked
264th among 535 active competitors
Employee Count
6 as on Apr 30, 2026
Similar Companies
Sign up to download Sapere Bio's company profile
Sapere Bio's funding and investors
Sapere Bio has raised a total funding of $500K over 5 rounds. Its first funding round was on Sep 30, 2014. Sapere Bio has 1 institutional investor.
Here is the list of recent funding rounds of Sapere Bio:
Filter this list
Filter this listDate of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
Jun 25, 2024 | 9976752 | Seed | 7133636 | 9946386 | 7392366 | 7438969 |
Sep 15, 2021 | 7609063 | Grant (prize money) | 9193582 | 8964759 | 8967688 | |
Sep 30, 2018 | 9245198 | Grant (prize money) | 3423423 | 1025815 | 1728333 |
Access funding benchmarks and valuations. Sign up today!View details of Sapere Bio's funding rounds and investors
Sapere Bio's founders and board of directors
Founder? Claim ProfileThe founders of Sapere Bio are Natalia Mitin and Norman Sharpless. Natalia Mitin is the CEO of Sapere Bio.
Here are the details of Sapere Bio's key team members:
- Natalia Mitin: Co-Founder & CEO of Sapere Bio.
- Norman Sharpless: Co-Founder of Sapere Bio.
View details of Sapere Bio's Founder profiles and Board Members
Sapere Bio's employee count trend
Sapere Bio has 6 employees as of Apr 26. Here is Sapere Bio's employee count trend over the years:
Uncover Sapere Bio's growth story! Sign up today!
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Sapere Bio's Competitors and alternates
Top competitors of Sapere Bio include Guardant Health, Natera and Myriad Genetics. Here is the list of Top 10 competitors of Sapere Bio, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Guardant Health 2012, Redwood City (United States), Public | Developer of digital sequencing technology for cancer detection | $557M | 79/100 | |
2nd | Natera 2004, Redwood City (United States), Public | Developer of cell-free DNA testing for oncology, women’s health, and organ health | $152M | 77/100 | |
3rd | Myriad Genetics 1991, United States, Public | Developer of molecular diagnostics and personalized medicine for cancer | - | 72/100 | |
4th | Foundation Medicine 2010, Cambridge (United States), Acquired | Provider of genomics-based diagnostics test for cancer | $96.5M | 71/100 | |
5th | Exact Sciences 1995, Madison (United States), Acquired | Provider of non-invasive molecular diagnostic testing solutions for cancer | - | 71/100 | |
6th | Caris Life Sciences 1996, Irving (United States), Public | Developer of panomic disease profiling technologies for cancer precision medicine | $1.23B | 71/100 | |
7th | Online platform for genetic and diagnostic health testing that helps identify health risks | $67.6M | 70/100 | ||
8th | BillionToOne 2015, San Francisco (United States), Public | Provider of cell-free cancer liquid biopsy test | $389M | 69/100 | |
9th | Delfi Diagnostics 2019, Baltimore (United States), Series B | Provider of DNA sequencing for cancer detection | $332M | 68/100 | |
10th |  Foresight Diagnostics 2020, Aurora (United States), Acquired | Developer of minimally-invasive liquid biopsy test for the detection of cancer | $104M | 66/100 | |
264th | Sapere Bio 2013, Raleigh (United States), Seed | Diagnostic company that develops non-invasive biomarker tests to measure cellular aging and predict the risk of age-related diseases | $500K | 28/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Sapere Bio's competitors? Click here to see the top ones
Sapere Bio's Investments and acquisitions
Sapere Bio has made no investments or acquisitions yet.
Are you a Founder ?
FAQs about Sapere Bio
Explore our recently published companies
- Alphainstruments - Unfunded company
- BauGPT - Munich based, 2022 founded, Funding Raised company
- Dryft - San Francisco based, 2024 founded, Seed company
- Quimas - Maipu based, 2003 founded, Unfunded company
- Process Tech - Salt Lake City based, 1996 founded, Unfunded company
- YTM - Raipur based, 2015 founded, Unfunded company
